Journal
PROTEOMICS CLINICAL APPLICATIONS
Volume 1, Issue 12, Pages 1582-1591Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200700414
Keywords
biomarker; ICAT; mass spectrometry; pancreatic cancer
Funding
- NCI NIH HHS [K07 CA116296, K07 CA116296-01A2, T32 CA080416, R01 CA107209] Funding Source: Medline
- NHLBI NIH HHS [N01HV28179] Funding Source: Medline
Ask authors/readers for more resources
Pancreatic cancer is the fourth leading cause of cancer death in the US, only 4% could survive 5 years after diagnosis. Biomarkers are desperately needed to improve earlier, more curable cancer diagnosis and to develop new effective therapeutic targets. The development of quantitative proteomics technologies in recent years offers great promise for understanding the complex molecular events of tumorigenesis at the protein level, and has stimulated great interest in applying the technology for pancreatic cancer studies. Proteomic studies of pancreatic tissues, juice, serum/plasma, and cell lines have recently attempted to identify differentially expressed proteins in pancreatic cancer to dissect the abnormal signaling pathways underlying oncogenesis, and to detect new biomarkers. It can be expected that the continuing evolution of proteomics technology with better resolution and sensitivity will greatly enhance our capability in combating pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available